RNTX
insider transactionsRein Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
+27.7K
27.7K buy · 0 sell
Net value · 30d
$29.3K
$29.3K in · $0 out
Sentiment · 30d
Net buying
100% buying · 0% selling
Open-market trades · 30d
2
27.7K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Buy·P
Director
$4.8K
4.5K sh · $1.07
Own +8%
-
Buy·P
Director
$24.5K
23.2K sh · $1.06
Own +67%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 27, 2026 | Josef H Von Rickenbach | Buy P | 4.5K | $4.8K |
| May 26, 2026 | Josef H Von Rickenbach | Buy P | 23.2K | $24.5K |
About RNTX insider trading
This page tracks insider transactions for Rein Therapeutics, Inc. (RNTX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.